

Deepak Kilari

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5745409/publications.pdf>

Version: 2024-02-01

55
papers

676
citations

687363

13
h-index

580821

25
g-index

55
all docs

55
docs citations

55
times ranked

1470
citing authors

#	ARTICLE	IF	CITATIONS
1	PROMISE: a real-world clinical-genomic database to address knowledge gaps in prostate cancer. Prostate Cancer and Prostatic Diseases, 2022, 25, 388-396.	3.9	15
2	Implications of androgen receptor (AR) alterations identified by genomic testing of tissue and blood from advanced prostate cancer (aPC) patients (pts).. Journal of Clinical Oncology, 2022, 40, 138-138.	1.6	0
3	DNA damaging therapies in patients (pts) with prostate cancer (PC) and pathogenic alterations in homologous recombination repair (HRR) genes.. Journal of Clinical Oncology, 2022, 40, 129-129.	1.6	0
4	Pathologic outcomes at cytoreductive nephrectomy (CN) following immunotherapy (IO) for patients with advanced renal cell carcinoma (RCC).. Journal of Clinical Oncology, 2022, 40, 334-334.	1.6	2
5	Impact of neoadjuvant immune checkpoint inhibitor therapy on primary tumor size and complexity: Correlation with surgical quality and short term oncological outcomes.. Journal of Clinical Oncology, 2022, 40, 390-390.	1.6	0
6	A single-arm, open-label, phase 2 study evaluating pacritinib for patients with biochemical recurrence after definitive treatment for prostate cancer: Blast study.. Journal of Clinical Oncology, 2022, 40, TPS220-TPS220.	1.6	0
7	Efficacy of enfortumab vedotin in advanced urothelial cancer: Analysis from the Urothelial Cancer Network to Investigate Therapeutic Experiences (UNITE) study. Cancer, 2022, 128, 1194-1205.	4.1	26
8	Outcomes with novel combinations in nonclear cell renal cell carcinoma (nccRCC): ORACLE study.. Journal of Clinical Oncology, 2022, 40, 4545-4545.	1.6	1
9	A phase 2 study of cabozantinib in combination with atezolizumab as neoadjuvant treatment for muscle-invasive bladder cancer (HCRN GU18-343) ABATE study.. Journal of Clinical Oncology, 2022, 40, TPS4618-TPS4618.	1.6	1
10	Biomarker-directed therapy in black and white men with metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2022, 40, 5013-5013.	1.6	0
11	Outcomes With Liver-Directed Therapy for Genitourinary Malignancies: Single-Institution Experience. Clinical Genitourinary Cancer, 2021, 19, 87-91.	1.9	1
12	Pembrolizumab plus enzalutamide for enzalutamide-resistant metastatic castration-resistant prostate cancer (mCRPC): Updated analyses after one additional year of follow-up from cohorts 4 and 5 of the KEYNOTE-199 study.. Journal of Clinical Oncology, 2021, 39, 5042-5042.	1.6	4
13	Outcomes with novel combinations in non-clear cell renal cell carcinoma(nccRCC): ORACLE study.. Journal of Clinical Oncology, 2021, 39, 4580-4580.	1.6	1
14	Phase I study of CCW702, a bispecific small molecule-antibody conjugate targeting PSMA and CD3 in patients with metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2021, 39, TPS5094-TPS5094.	1.6	7
15	Efficacy of anti-PD(L)1 therapy for patients (Pts) with advanced urothelial carcinoma (aUC) with primary resistance to platinum-based chemotherapy (PC).. Journal of Clinical Oncology, 2021, 39, e16515-e16515.	1.6	1
16	A phase 2 study of cabozantinib in combination with atezolizumab as neoadjuvant treatment for muscle-invasive bladder cancer (HCRN GU18-343) ABATE study.. Journal of Clinical Oncology, 2021, 39, TPS4591-TPS4591.	1.6	0
17	Talazoparib (TALA), an oral poly (ADP-ribose) polymerase (PARP) inhibitor for men with metastatic castration-resistant prostate cancer (mCRPC) and DNA damage response (DDR) alterations: Detailed safety analyses from TALAPRO-1 trial.. Journal of Clinical Oncology, 2021, 39, 5047-5047.	1.6	1
18	Second-Generation Jak2 Inhibitors for Advanced Prostate Cancer: Are We Ready for Clinical Development?. Cancers, 2021, 13, 5204.	3.7	13

#	ARTICLE	IF	CITATIONS
19	294â€¦..Evaluation of radiographic response in the intact renal mass (intact-Rmass) to immune checkpoint inhibitor (ICI) combination regimens in patients with metastatic renal cell carcinoma (mRCC). , 2021, 9, A318-A318.		1
20	Enzalutamide-Induced Feed-Forward Signaling Loop Promotes Therapy-Resistant Prostate Cancer Growth Providing an Exploitable Molecular Target for Jak2 Inhibitors. Molecular Cancer Therapeutics, 2020, 19, 231-246.	4.1	16
21	The Role of Metastasectomy in Urothelial Carcinoma: Where Are We in 2020?. Clinical Genitourinary Cancer, 2020, 18, e478-e483.	1.9	3
22	Salvage ipilimumab associated with a significant response in sarcomatoid renal cell carcinoma. , 2020, 8, e000584.		4
23	Exceptional Response to Everolimus in a Patient with Metastatic Castrate-Resistant Prostate Cancer Harboring a PTEN Inactivating Mutation. Case Reports in Oncology, 2020, 13, 456-461.	0.7	2
24	<i>CDK12</i>-Mutated Prostate Cancer: Clinical Outcomes With Standard Therapies and Immune Checkpoint Blockade. JCO Precision Oncology, 2020, 4, 382-392.	3.0	51
25	KEYNOTE-199 cohorts (C) 4 and 5: Phase II study of pembrolizumab (pembro) plus enzalutamide (enza) for enza-resistant metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2020, 38, 5543-5543.	1.6	17
26	First-line PD-1/PD-L1 inhibitor monotherapy for advanced renal cell carcinoma (aRCC): A multi-institutional cohort.. Journal of Clinical Oncology, 2020, 38, e17109-e17109.	1.6	2
27	Pembrolizumab (pembro) plus enzalutamide (enza) for enza-resistant metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-199 cohorts 4-5.. Journal of Clinical Oncology, 2020, 38, 15-15.	1.6	15
28	CDK12-mutated prostate cancer (PC): Clinical outcomes to standard therapies and immune checkpoint blockade.. Journal of Clinical Oncology, 2020, 38, 191-191.	1.6	3
29	Concurrent durvalumab and radiation therapy followed by adjuvant durvalumab in patients with locally advanced urothelial cancer of bladder (DUART): Btcr-GU15-023.. Journal of Clinical Oncology, 2020, 38, 513-513.	1.6	9
30	Hcrn GU15-215: A phase II trial of atezolizumab (atezo) and bevacizumab (bev) in cisplatin-ineligible patients (pts) with advanced/unresectable urothelial cancer (UC).. Journal of Clinical Oncology, 2020, 38, TPS5098-TPS5098.	1.6	0
31	Emerging clinical phenotype of bone metastatic urothelial cancer (mUC): Association of early osseous metastases (EOM) and outcomes.. Journal of Clinical Oncology, 2020, 38, e17007-e17007.	1.6	0
32	Palliative care education for oncologists: how are we doing?. Annals of Palliative Medicine, 2019, 8, 364-371.	1.2	7
33	Autologous Hematopoietic Stem Cell Transplantation for Male Germ Cell Tumors: Improved Outcomes Over 3 Decades. Biology of Blood and Marrow Transplantation, 2019, 25, 1099-1106.	2.0	12
34	The role of enzalutamide-induced hyperactive Jak2-Stat5 feed-forward signaling loop on enzalutamide-resistant prostate cancer growth and as a therapeutic target for second-line treatment.. Journal of Clinical Oncology, 2019, 37, 221-221.	1.6	2
35	A phase II study of enzalutamide (Enz) with dutasteride (Dut) or finasteride (Fin) in men â‰¥ 65 years with hormone-naïve systemic prostate cancer (HNSPCa): Tolerability and geriatric assessment (GA) results.. Journal of Clinical Oncology, 2019, 37, e16518-e16518.	1.6	0
36	Immune Checkpoint Inhibitor-Associated Type 1 Diabetes Mellitus: Case Series, Review of the Literature, and Optimal Management. Case Reports in Oncology, 2018, 10, 897-909.	0.7	57

#	ARTICLE	IF	CITATIONS
37	Enfortumab vedotin (EV) in patients (Pts) with metastatic urothelial carcinoma (mUC) with prior checkpoint inhibitor (CPI) failure: A prospective cohort of an ongoing phase 1 study.. Journal of Clinical Oncology, 2018, 36, 431-431.	1.6	4
38	Tandem high-dose chemotherapy and autologous hematopoietic stem cell transplantation (SCT) compared to single SCT for relapsed/refractory germ cell tumors (GCT).. Journal of Clinical Oncology, 2018, 36, 572-572.	1.6	0
39	Liver-directed therapy (LDT) for metastatic renal cell carcinoma (mRCC): Single center experience.. Journal of Clinical Oncology, 2018, 36, 681-681.	1.6	0
40	Effect of β -hydroxy- β -methylbutyrate (HMB) on muscle strength in older men with prostate cancer (Pca) started on androgen deprivation therapy (ADT): Preliminary results of an open-label, randomized trial.. Journal of Clinical Oncology, 2018, 36, 258-258.	1.6	0
41	Immune Check Point Inhibition in Sarcomatoid Renal Cell Carcinoma: A New Treatment Paradigm. Clinical Genitourinary Cancer, 2017, 15, e897-e901.	1.9	12
42	Applications of Extracellular RNAs in Oncology. Molecular Diagnosis and Therapy, 2017, 21, 1-11.	3.8	7
43	Androgen receptor-dependent and -independent mechanisms driving prostate cancer progression: Opportunities for therapeutic targeting from multiple angles. Oncotarget, 2017, 8, 3724-3745.	1.8	95
44	A phase II study of enzalutamide (Enz) with dutasteride (Dut) or finasteride (Fin) in men \geq 65 years with hormone-naïve systemic prostate cancer (HNSPCa).. Journal of Clinical Oncology, 2017, 35, 179-179.	1.6	0
45	Predictors of response to platinum (Pt)-based chemotherapy in metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2017, 35, e575-e575.	1.6	0
46	Association of mannitol (MAN) with cisplatin (CIS)-induced nephrotoxicity (NTX) and cumulative CIS dose (CCD).. Journal of Clinical Oncology, 2017, 35, 6051-6051.	1.6	0
47	Gaps in nutritional research among older adults with cancer. Journal of Geriatric Oncology, 2016, 7, 281-292.	1.0	47
48	Designing exercise clinical trials for older adults with cancer: Recommendations from 2015 Cancer and Aging Research Group NCI U13 Meeting. Journal of Geriatric Oncology, 2016, 7, 293-304.	1.0	58
49	Platinum Concentration and Pathologic Response to Cisplatin-Based Neoadjuvant Chemotherapy in Muscle-Invasive Bladder Cancer. PLoS ONE, 2016, 11, e0155503.	2.5	7
50	Role of copper transporters in platinum resistance. World Journal of Clinical Oncology, 2016, 7, 106.	2.3	99
51	Copper Transporter-CTR1 Expression and Pathological Outcomes in Platinum-treated Muscle-invasive Bladder Cancer Patients. Anticancer Research, 2016, 36, 495-501.	1.1	28
52	Plasma genetic and genomic abnormalities predict treatment response and clinical outcome in advanced prostate cancer. Oncotarget, 2015, 6, 16411-16421.	1.8	36
53	Platinum concentration in bladder tissue treated with neoadjuvant chemotherapy and pathologic response.. Journal of Clinical Oncology, 2015, 33, 341-341.	1.6	0
54	How we treat early systemic prostate cancer in older men. Journal of Geriatric Oncology, 2014, 5, 337-342.	1.0	7

#	ARTICLE	IF	CITATIONS
55	Association between copper transporter receptor 1(CTR1) expression and pathologic outcomes in cisplatin (Pt)-treated bladder cancer (BC) patients.. Journal of Clinical Oncology, 2014, 32, e15516-e15516.	1.6	2